Urinary CD14 as a potential biomarker for benign prostatic hyperplasia – discovery by combining MALDI‐TOF‐based biostatistics and ESI‐MS/MS‐based stable‐isotope labeling
Authors:
- 10 January 2011
- journal article
- research article
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 5 (3-4) , 121-132
Abstract
Purpose: Quest for specific urinary biomarkers for benign prostatic hyperplasia (BPH).Experimental design: Proteomics studies were conducted with urines of the training set to discovering marker candidates that could differentiate BPH from normal subjects by matching results deduced from MALDI‐TOF of individual samples and results deduced from nanoLC‐ESI‐MS/MS‐based stable isotope dimethyl labeling of two pooled samples (BPH and normal). Samples were digested before analysis and such an approach takes into account the subject‐to‐subject variation and differential amount, as well as protein identification. Selected markers were validated by ELISA conducted on the training set and the test set as well as another set of urines collected from prostate cancer patients.Results: Nine marker candidates were identified from proteomics studies; CD14, prostate‐specific antigen and pancreatic α‐amylase precursor were further selected for ELISA validation. Urinary CD14 is among the best match with high specificity (>81%) for both training and test sets. In addition, from the study of prostate cancer patients, CD14 also allows the distinction of BPH from cancer with high specificity (84–100%) when combined with urinary prostate‐specific antigen.Conclusions and clinical relevance: Urinary CD14 is suggested to have a high specificity in the diagnosis of BPH in distinction from normal as well as cancer subjects.Keywords
Funding Information
- National Science Council of Taiwan (NSC-98-2922-I-006-051)
- Clinical Proteome Core (DOH-TD-B-111-004)
- Medical College & Hospital in Departments of Urology and Pathology of the National Cheng Kung University Hospital (NCKUH-9803021)
This publication has 29 references indexed in Scilit:
- Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urineBiochemical and Biophysical Research Communications, 2006
- Label-free Quantitative Proteomics Using Large Peptide Data Sets Generated by Nanoflow Liquid Chromatography and Mass SpectrometryMolecular & Cellular Proteomics, 2006
- Concanavalin A-captured Glycoproteins in Healthy Human UrineMolecular & Cellular Proteomics, 2006
- Prognostic significance of osteopontin expression in human prostate cancerInternational Journal of Cancer, 2005
- Stable-Isotope Dimethyl Labeling for Quantitative ProteomicsAnalytical Chemistry, 2003
- Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), α‐1‐antichymotrypsin (ACT), and the PSA–ACT complexThe Prostate, 2003
- Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinomaProteomics, 2003
- Prostate specific antigen complexed to α‐1‐antichymotrypsin in patients with intermediate prostate specific antigen levelsCancer, 2002
- Biomarker Discovery in Urine by ProteomicsJournal of Proteome Research, 2002
- Measuring the Accuracy of Diagnostic SystemsScience, 1988